Evidence map›Paper›PMID 31089379›Full record

ArticleIranian journal of pharmaceutical research : IJPR2019

Formulation and Optimization of a New Cationic Lipid-Modified PLGA Nanoparticle as Delivery System for

Farzad Khademi, Arshid Yousefi-Avarvand, Mohammad Derakhshan, Mohammad Reza Abbaspour, Kayvan Sadri, Mohsen Tafaghodi

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Multi-functionalized nanocarriers targeting bacterial reservoirs to overcome challenges of multi drug-resistance.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Farzad KhademiDepartment of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Arshid Yousefi-AvarvandAntimicrobial Resistance Research Center, Department of Medical Bacteriology and Virology, Qaem University Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad DerakhshanAntimicrobial Resistance Research Center, Department of Medical Bacteriology and Virology, Qaem University Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad Reza AbbaspourTargeted Drug Delivery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Kayvan SadriNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohsen TafaghodiNanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Mashhad University of Medical Sciences · IRArdabil University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polymeric particles and liposomes are efficient tools to overcome the low immunogenicity of subunit vaccines. The aim of the present study was formulation and optimization of a new cationic lipid-modified PLGA nanoparticles (NPs) as a delivery system for

Indexed as

Experimental designHspX/EsxS fusion proteinMycobacterium tuberculosisPLGA:DDA hybrid nanoparticle

Identifiers

PMID31089379
PMCPMC6487422
OpenAlexW2894795711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.